

## FOI 5188 - Chemotherapy data for haematological cancers and other haematological conditions

Questions	Notes/Comments	Response	
1. Does your trust treat adult multiple myeloma [MM] ? - if you refer your multiple myeloma patients to another centre, please state which.		Yes	
2. If yes, then how many MM patients, have been treated in the past 6 months with the the following?	Patients treated between August 2019 and January 2020.	<b>Regimen Name</b>	<b>Number of patients</b>
		Bortezomib [Velcade]	3
		Carfilzomib [Kyprolis]	0
		Ixazomib [Ninlaro]	0
		Lenalidomide [Revlimid]	2
		Daratumumab [Darzalex]	6
		Melphalan, prednisolone and thalidomide (known as MPT)	0
		Cyclophosphamide, thalidomide and dexamethasone (known as CTD)	0
		Pomalidomide [Imnovid]	4
3. Over the past 6 months [latest possible], how many chronic lymphocytic leukaemia (CLL) patients have you treated? If possible how many CLL patients treated were new to therapy in the past 3 months?	Patients treated between August 2019 and January 2020. The Performance and Information department are only able to provide the number of CLL patients treated in the Last 6 months.	27	
4. How many chronic lymphocytic leukaemia patients, have been treated in the past 6 months with the following;	Patients treated between August 2019 and January 2020.	<b>Regimen Name</b>	<b>Number of patients</b>
		Fludarabine (Fludara), cyclophosphamide (Cytosan), and rituximab (known as FCR)	1
		Bendamustine and rituximab (known as BR)	1
		Ibrutinib [Imbruvica]	9
		Chlorambucil	1
		Venetoclax	2
		Obinutuzumab	4
		Idelalisib	0
		Fludarabine and rituximab (known as FR)	0
		High-dose prednisone and rituximab	0
		Pentostatin (Nipent), cyclophosphamide, and rituximab (known as PCR)	0
		Alemtuzumab (Campath) with rituximab	0